A person recently approached me at church with excitement regarding a software process he developed. His company was so pleased with the result that it is filing a patent, listing him as the inventor. This person knew that I had some kind of patent backstory, so he asked for my thoughts. My name is Jeffrey A. Killian, and I am the patent applicant in the Federal Circuit Court case # 2021 -2113 (In Re: Killian). I took no pleasure in telling my  friend at church that his patent application will be rejected. Plus, the official notice will have my precedential case quoted all over his rejection. With friends at church like me, who needs enemies? 

Trademark claims against Netflix concerning its popular “Running Point” comedy series were recently dismissed at the pleadings stage due to a one-letter misarticulation of applicable First Amendment law. The case, soon to be litigated on appeal, highlights the need to clarify the contours of trademark liability arising from creative works. Pepperdine University filed the lawsuit last year against Netflix and co-defendants Warner Bros. and Kaling International, just one week before the “Running Point” series premiere.  Loosely based on the life of Los Angeles Lakers owner Jeanie Buss, the series stars Kate Hudson as the owner of the fictional basketball team the Los Angeles Waves. The popular series, which amassed instant popularity and ranked as Netflix’s #1 TV show, was quickly ordered for a second season that premiered April 23, 2026.

This week on IPWatchdog Unleashed, I spoke with Brent Bellows, a partner with Knowles Intellectual Property Strategies (KIPS). We discussed a variety of issues including Hatch-Waxman, Orange Book listings, paragraph IV certifications, skinny labels, generic entry, clinical trial costs, regulatory exclusivity, and the enormous financial risk associated with bringing new drugs to market. Gene and Brent explore the tension between public demand for lower drug prices and the need for durable incentives that make high-risk drug development economically viable, particularly for oncology, Alzheimer’s, Parkinson’s, antibiotic resistant bacteria, and other difficult-to-treat conditions. The episode closes with a broader innovation-policy message: patents are not a peripheral feature of drug development—they are a core operating asset that enables private-sector investment, supports breakthrough therapies, and ultimately drives the availability of future generic medicines.